Hubei Jumpcan Pharmaceutical Co., Ltd. (SHA:600566)
China · Delayed Price · Currency is CNY 27.48
-0.10 (-0.36%)
Jun 9, 2026, 3:00 PM CST
SHA:600566 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 5,887 | 6,205 | 7,997 | 9,638 | 8,976 | 7,618 |
Other Revenue | 14.11 | 14.11 | 20.38 | 16.51 | 19.87 | 13 |
| 5,901 | 6,219 | 8,017 | 9,655 | 8,996 | 7,631 | |
Revenue Growth (YoY) | -17.35% | -22.43% | -16.96% | 7.32% | 17.90% | 23.77% |
Cost of Revenue | 1,178 | 1,309 | 1,666 | 1,784 | 1,537 | 1,277 |
Gross Profit | 4,723 | 4,909 | 6,350 | 7,871 | 7,459 | 6,354 |
Selling, General & Admin | 2,431 | 2,559 | 3,387 | 4,379 | 4,477 | 4,031 |
Research & Development | 390.98 | 385.1 | 444.78 | 464.4 | 553.3 | 523.44 |
Other Operating Expenses | 96.02 | 105.98 | 114.37 | 146.24 | 138.81 | 120.9 |
Operating Expenses | 2,913 | 3,055 | 3,924 | 4,987 | 5,205 | 4,683 |
Operating Income | 1,810 | 1,855 | 2,427 | 2,884 | 2,254 | 1,671 |
Interest Expense | -14.11 | -11.45 | -27.27 | -17.58 | -30.41 | -34.9 |
Interest & Investment Income | 267.14 | 256.71 | 352.77 | 357.81 | 183.21 | 171.42 |
Currency Exchange Gain (Loss) | -0.01 | -0.01 | - | - | - | - |
Other Non Operating Income (Expenses) | -11.88 | -0.8 | -1.03 | -0.83 | -1.2 | -0.41 |
EBT Excluding Unusual Items | 2,051 | 2,099 | 2,751 | 3,223 | 2,405 | 1,807 |
Gain (Loss) on Sale of Investments | 48.64 | 41.31 | 99.2 | 14.6 | -7.32 | 114.55 |
Gain (Loss) on Sale of Assets | 0.17 | 0.17 | 0.2 | 0.13 | 5.22 | 0.65 |
Asset Writedown | -0.45 | -0.45 | -0.28 | -1.09 | -0.53 | -0.42 |
Other Unusual Items | 22.17 | 22.17 | 127.97 | 60.42 | 105.09 | 28.96 |
Pretax Income | 2,122 | 2,162 | 2,978 | 3,297 | 2,508 | 1,950 |
Income Tax Expense | 385.72 | 383.99 | 441.54 | 470.03 | 336.2 | 233.22 |
Earnings From Continuing Operations | 1,736 | 1,778 | 2,537 | 2,827 | 2,172 | 1,717 |
Minority Interest in Earnings | 1.62 | -0.41 | -5.15 | -4.28 | -0.97 | 1.96 |
Net Income | 1,738 | 1,778 | 2,532 | 2,823 | 2,171 | 1,719 |
Net Income to Common | 1,738 | 1,778 | 2,532 | 2,823 | 2,171 | 1,719 |
Net Income Growth | -18.29% | -29.77% | -10.32% | 30.04% | 26.27% | 34.60% |
Shares Outstanding (Basic) | 919 | 921 | 917 | 916 | 890 | 886 |
Shares Outstanding (Diluted) | 919 | 921 | 917 | 916 | 908 | 900 |
Shares Change (YoY) | 0.25% | 0.43% | 0.08% | 0.91% | 0.91% | 7.82% |
EPS (Basic) | 1.89 | 1.93 | 2.76 | 3.08 | 2.44 | 1.94 |
EPS (Diluted) | 1.89 | 1.93 | 2.76 | 3.08 | 2.39 | 1.91 |
EPS Growth | -18.50% | -30.07% | -10.39% | 28.87% | 25.13% | 24.84% |
Free Cash Flow | 1,021 | 1,102 | 2,002 | 3,162 | 2,377 | 1,646 |
Free Cash Flow Per Share | 1.11 | 1.20 | 2.18 | 3.45 | 2.62 | 1.83 |
Dividend Per Share | 1.740 | 1.740 | 2.090 | 1.300 | 0.880 | 0.680 |
Dividend Growth | -16.75% | -16.75% | 60.77% | 47.73% | 29.41% | 51.11% |
Gross Margin | 80.04% | 78.95% | 79.21% | 81.52% | 82.91% | 83.27% |
Operating Margin | 30.68% | 29.82% | 30.27% | 29.87% | 25.05% | 21.89% |
Profit Margin | 29.45% | 28.59% | 31.58% | 29.24% | 24.13% | 22.53% |
Free Cash Flow Margin | 17.30% | 17.73% | 24.97% | 32.76% | 26.42% | 21.57% |
EBITDA | 2,107 | 2,154 | 2,733 | 3,185 | 2,561 | 1,964 |
EBITDA Margin | 35.71% | 34.63% | 34.09% | 32.99% | 28.47% | 25.74% |
D&A For EBITDA | 297.27 | 299.16 | 306.7 | 301.2 | 307.14 | 293.13 |
EBIT | 1,810 | 1,855 | 2,427 | 2,884 | 2,254 | 1,671 |
EBIT Margin | 30.68% | 29.82% | 30.27% | 29.87% | 25.05% | 21.89% |
Effective Tax Rate | 18.18% | 17.76% | 14.83% | 14.26% | 13.41% | 11.96% |
Revenue as Reported | 5,901 | 6,219 | 8,017 | 9,655 | 8,996 | 7,631 |